WASHINGTON — A phase 2 study has demonstrated encouraging results for lutetium-177 (177Lu) dotatate in patients with surgery- and radiation-refractory meningioma. Kenneth Merrell, MD, MS, presented ...
Discover comprehensive details about Lutetium Lu 177 Dotatate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...
Toronto, Ontario—A novel imaging approach— 68 Ga-DOTATATE PET/CT—can more accurately differentiate residual/recurrent tumors from post-surgery scar tissue in patients with head and neck paragangliomas ...
ST. LOUIS, July 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has submitted its 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection ...
Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...
June 21, 2012 (Miami Beach, Florida) — Molecular imaging with a method that detects hormonally active tissues in the body can improve the care of patients with neuroendocrine cancer, researchers said ...
Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients ...
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback